Literature DB >> 30193265

Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.

Steven Kozlowski1, Noy Birger2, Stephaeno Brereton2, Stephen J McKean2, Michael Wernecke2, Leah Christl1, Jeffrey A Kelman3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30193265      PMCID： PMC6142991          DOI： 10.1001/jama.2018.9014

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Biosimilars and the European experience: implications for the United States.

Authors:  Francis Megerlin; Ruth Lopert; Ken Taymor; Jean-Hugues Trouvin
Journal:  Health Aff (Millwood)       Date:  2013-10       Impact factor: 6.301

2.  Biosimilar competition: lessons from Europe.

Authors:  Henry Grabowski; Rahul Guha; Maria Salgado
Journal:  Nat Rev Drug Discov       Date:  2014-01-21       Impact factor: 84.694
  2 in total
  10 in total

1.  Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Authors:  Kaniz Afroz Tanni; Cong Bang Truong; Sura Almahasis; Jingjing Qian
Journal:  BioDrugs       Date:  2021-01-13       Impact factor: 5.807

2.  Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.

Authors:  Joshua F Baker; Charles E Leonard; Vincent Lo Re; Michael H Weisman; Michael D George; Jonathan Kay
Journal:  Arthritis Rheumatol       Date:  2020-05-05       Impact factor: 10.995

3.  Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.

Authors:  Morgane C Mouslim; Antonio J Trujillo; G Caleb Alexander; Jodi B Segal
Journal:  Value Health       Date:  2020-10-23       Impact factor: 5.725

4.  Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.

Authors:  Mariana P Socal; Kelly E Anderson; Aditi Sen; Ge Bai; Gerard F Anderson
Journal:  Value Health       Date:  2020-02-17       Impact factor: 5.725

5.  Uptake of Infliximab Biosimilars Among the Medicare Population.

Authors:  Alice J Chen; Laura Gascue; Rocio Ribero; Karen Van Nuys
Journal:  JAMA Intern Med       Date:  2020-09-01       Impact factor: 21.873

6.  Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population.

Authors:  Steven Kozlowski; Natasha Flowers; Noy Birger; Michael Wernecke; Thomas E MaCurdy; Jeffrey A Kelman; David J Graham
Journal:  J Gen Intern Med       Date:  2020-06-23       Impact factor: 6.473

7.  Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.

Authors:  Prasad L Gawade; Shuling Li; David Henry; Nancy Smith; Rajesh Belani; Michael A Kelsh; Brian D Bradbury
Journal:  Support Care Cancer       Date:  2020-01-10       Impact factor: 3.603

8.  Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.

Authors:  Emma Boswell Dean; Phyllis Johnson; Amelia M Bond
Journal:  JAMA Netw Open       Date:  2021-01-04

9.  Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.

Authors:  Ching-Yu Wang; Coy D Heldermon; Scott M Vouri; Haesuk Park; Sarah E Wheeler; Brian Hemendra Ramnaraign; Nam Hoang Dang; Joshua D Brown
Journal:  JAMA Netw Open       Date:  2021-11-01

10.  Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.

Authors:  Sean R Dickson; Tyler Kent
Journal:  JAMA Netw Open       Date:  2021-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.